- Over the weekend, both the White House and Trump sang praise of Regeneron’s experimental antibody cocktail REGN-COV2
- After the video posted, Regeneron stock jumped three per cent
- When markets opened on Monday, Regeneron stock prices went from $564 to over $600 a share
- Joseph Goldstein, who sits on the board of directors for Regeneron, and SVP and Head of Commercial Marion McCourt sold a total of 10,200 shares
- Exercising their stock options allowed the pair to make a net profit of over $1million – around $740,000 for Goldstein and $260,000 for McCourt
By Matthew Wright | 11 October 2020
DAILY MAIL — Two executives at Regeneron sold $1million in stocks just two after President Donald Trump announced that he had been taking their drug to help recover from COVID-19, according to recent filings from the Securities and Exchange Commission (SEC).
Over the weekend, both the White House and Trump sang praise of Regeneron’s experimental antibody cocktail that has not been approved by the Food and Drug Administration nor has it passed trials.
‘They gave me Regeneron,’ Trump said in a video he posted to Twitter on October 3 about his treatment at Walter Reed National Military Medical Center. ‘It was like, unbelievable. I felt good immediately. I felt as good three days ago as I do now.’ […]